Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline
Institute of Oncology Research · Vall d'Hebron Institute of Oncology · +27 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
268
total citations
- FWCI
- 42.50
- Percentile
- 100%
- References
- 118
Citations per year
Authors
18- CSCristiana SessaCorresponding
Institute of Oncology Research
- JBJudith Balmañà
Vall d'Hebron Institute of Oncology
- SLSharon L. Bober
Boston University, Harvard University, Dana-Farber Cancer Institute
- MJMaria João Cardoso
Champalimaud Foundation
- NCN. Colombo
European Institute of Oncology, University of Milano-Bicocca
Topics & keywords
Topics
Keywords
- Medicine
- Ovarian cancer
- Family history
- Oncology
- Breast cancer
- Guideline
- Internal medicine
- Cancer
No related works found for this paper.
Funding
- ELEli Lilly and Company
- PPfizer
- AAstraZeneca
- NINational Institute for Health and Care ResearchAwards: BRC-1215-20007, IS-BRC-1215, IS-BRC-1215-20007
- AIAssociazione Italiana per la Ricerca sul CancroAwards: IS-BRC-1215-20007, 24698, MFAG 2020 ID 24698, MFAG 2020
- ESEuropean Society for Medical Oncology
- MBManchester Biomedical Research CentreAwards: IS-BRC-1215-20007, BRC-1215-20007, 20007, IS-BRC-1215
- MRMedical Research CouncilAward: IS-BRC-1215-20007
- NHNational Health and Medical Research CouncilAward: IS-BRC-1215-20007